- ASSOCIATE PROFESSOR Pharmacology and Systems Therapeutics
B.Sc., Bombay University
M.Sc., Bombay University
Ph.D., All India Institute of Medical Sciences
- Dr. Gomes is a member of the Devi Laboratory within the Department of Pharmacology and Systems Therapeutics.
1987 - 1992
All India Institute of Medical Sciences Ph.D. Fellowship
Exploration of the functional implications of the heterodimerization between opioid receptors and other G-protein coupled receptors
My primary research interests include the investigation of G-protein coupled receptor cross-talk and mechanisms involved in G-protein coupled receptor heterodimerization/oligomerization. We have shown that two functional receptors- mu and delta opioid receptors- associate with each other (i.e. heterodimerize) to form complexes with pharmacological and signaling properties quite distinct from each individual receptor. Occupancy of the delta opioid receptor with a low non-activating dose of selective delta drugs increases the binding and signaling properties of agonists acting at the mu receptors. This work provides a model for the development of a new generation of narcotic analgesics which would have a lower tendency to induce side-effects such as addiction and tolerance. We have also shown that mu opioid receptor signaling can be modulated by heterodimerization with either alpha 2A or CB1 cannabinoid receptors. We are currently investigating the mechanisms involved as well as the physiological relevance of receptor heterodimerization.
Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, Battini L, Gusella GL, Lachmann A, Ma'ayan A, Blitzer RD, Devi LA. Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PloS One 2012; 7(1).
Abul-Husn NS, Annangudi SP, Ma'ayan A, Ramos-Ortolaza DL, Stockton SD, Gomes I, Sweedler JV, Devi LA. Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis. PloS One 2011; 6(10).
Gupta A, Devi LA, Gomes I. Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem 2011 Oct; 119(2).
Rozenfeld R, Gupta A, Gagnidze K, Lim MP, Gomes I, Lee-Ramos D, Nieto N, Devi LA. AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J 2011 Jun; 30(12).
Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA. G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 2011 Jun; 79(6).
Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, Lim M, Maillet E, Junek M, Cahill CM, Harkany T, Devi LA. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010 July; 3(131): rs54.
Morgan DJ, Wei S, Gomes I, Czyzyk T, Mzhavia N, Pan H, Devi LA, Fricker LD, Pintar JE. The propeptide precursor proSAAS is involved in fetal neuropeptide processing and body weight regulation. J Neurochem 2010 Jun; 113(5): 1275-1284.
Moron JA, Gullapalli S, Taylor C, Gupta A, Gomes I, Devi LA. Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation. Neuropsychopharmacology 2010 Mar; 35(4): 955-966.
Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heinmann AS, Ferro ES, Scarlata S, Fricker LD, Devi LA. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J 2009 Sep; 23(9).
Alfaras-Melainis K, Gomes I, Rozenfeld R, Zachariou V, Devi L. Modulation of opioid receptor function by protein-protein interactions. Front Biosci 2009 Jan; 14: 3594-35607.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Gomes did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Annenberg Building Floor 19th Room 19-86
1468 Madison Avenue
New York, NY 10029